Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Docetaxel + Prednisone |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Docetaxel | Taxotere | RP56976 | Antimicrotubule Agent 14 | Taxotere (docetaxel) binds to tubulin, inhibiting microtubule disassembly and preventing cell division (PMID: 32496783, PMID: 32366558). |
Prednisone | Adasone | Dehydrocortisone | Adasone (prednisone) is a corticosteroid which functions as an immunosuppressant and anti-inflammatory agent and which may stimulate apoptosis in tumor cells (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04100018 | Phase III | Docetaxel + Nivolumab + Prednisone Docetaxel + Prednisone | A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate Cancer (CheckMate 7DX) | Active, not recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS | 18 |
NCT03834506 | Phase III | Docetaxel + Prednisone Dexamethasone + Docetaxel + Pembrolizumab + Prednisone | Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921) | Completed | USA | ITA | GBR | FRA | ESP | DEU | CAN | AUT | AUS | 12 |
NCT01619813 | Phase II | Docetaxel + Prednisone Pelareorep | Reolysin Combined With Docetaxel and Prednisone or Docetaxel and Prednisone Alone in Metastatic Castration Resistant Prostate Cancer | Completed | CAN | 0 |
NCT05848011 | Phase II | Docetaxel + MGD019 + Prednisone Docetaxel + Prednisone | A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer | Recruiting | USA | FRA | ESP | 1 |
NCT03761225 | Phase III | Docetaxel + Prednisone Docetaxel + Masitinib + Prednisone | Masitinib Plus Docetaxel in Metastatic Castration-resistant Prostate Cancer | Completed | ITA | FRA | CAN | 3 |
NCT02685267 | Phase II | Docetaxel + Enzalutamide + Prednisone Docetaxel + Prednisone | Docetaxel/Prednisone Versus Docetaxel/Prednisone and Enzalutamide in Castration-Resistant Prostate Cancer (Doce/Enza) | Terminated | USA | 0 |